Bhanu Kanth Manne

Bhanu Kanth Manne

Auto-generated profile, based on publicly available information

Bhanu Kanth Manne

University of Utah Molecular Medicine Program, Salt Lake City, Utah, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2020 in Blood
Verified
Journal Article
Open access
PDF file
EMElizabeth A. Middleton
Elizabeth A. Middleton
XHXue-Yan He
Xue-Yan He
FDFrederik Denorme
Frederik Denorme
RCRobert A. Campbell
Robert A. Campbell
DNDavid Ng
David Ng
CYChristian Con Yost
Christian Con Yost
COVID-19 affects millions of patients worldwide, with clinical presentation ranging from isolated thrombosis to acute respiratory distress syndrome (ARDS) requiring ventilator support. Neutrophil extracellular traps (NETs) originate from decondensed chromatin released to immobilize pathogens, and they can trigger immunothrombosis. We studied the connection between NETs and COVID-19 severity and progression. We conducted a prospective cohort study of COVID-19 patients (n = 33) and age- and sex-matched controls (n = 17). We measured plasma myeloperoxidase (MPO)-DNA complexes (NETs), platelet factor 4, RANTES, and selected cytokines. Three COVID-19 lung autopsies were examined for NETs and platelet involvement. We assessed NET formation ex vivo in COVID-19 neutrophils and in healthy neutrophils incubated with COVID-19 plasma. We also tested the ability of neonatal NET-inhibitory factor (nNIF) to block NET formation induced by COVID-19 plasma. Plasma MPO-DNA complexes increased in COVID-19, with intubation (P < .0001) and death (P < .0005) as outcome. Illness severity correlated directly with plasma MPO-DNA complexes (P = .0360), whereas Pao2/fraction of inspired oxygen correlated inversely (P = .0340). Soluble and cellular factors triggering NETs were significantly increased in COVID-19, and pulmonary autopsies confirmed NET-containing microthrombi with neutrophil-platelet infiltration. Finally, COVID-19 neutrophils ex vivo displayed excessive NETs at baseline, and COVID-19 plasma triggered NET formation, which was blocked by nNIF. Thus, NETs triggering immunothrombosis may, in part, explain the prothrombotic clinical presentations in COVID-19, and NETs may represent targets for therapeutic intervention.

10 September 2020 in Blood
Verified
Journal Article
Open access
PDF file
BMBhanu Kanth Manne
Bhanu Kanth Manne
FDFrederik Denorme
Frederik Denorme
EMElizabeth A. Middleton
Elizabeth A. Middleton
IPIrina Portier
Irina Portier
JRJesse W. Rowley
Jesse W. Rowley
HCHeather Campbell
Heather Campbell
There is an urgent need to understand the pathogenesis of coronavirus disease 2019 (COVID-19). In particular, thrombotic complications in patients with COVID-19 are common and contribute to organ failure and mortality. Patients with severe COVID-19 present with hemostatic abnormalities that mimic disseminated intravascular coagulopathy associated with sepsis, with the major difference being increased risk of thrombosis rather than bleeding. However, whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection alters platelet function to contribute to the pathophysiology of COVID-19 remains unknown. In this study, we report altered platelet gene expression and functional responses in patients infected with SARS-CoV-2. RNA sequencing demonstrated distinct changes in the gene-expression profile of circulating platelets of COVID-19 patients. Pathway analysis revealed differential gene-expression changes in pathways associated with protein ubiquitination, antigen presentation, and mitochondrial dysfunction. The receptor for SARS-CoV-2 binding, angiotensin-converting enzyme 2 (ACE2), was not detected by messenger RNA (mRNA) or protein in platelets. Surprisingly, mRNA from the SARS-CoV-2 N1 gene was detected in platelets from 2 of 25 COVID-19 patients, suggesting that platelets may take-up SARS-COV-2 mRNA independent of ACE2. Resting platelets from COVID-19 patients had increased P-selectin expression basally and upon activation. Circulating platelet-neutrophil, -monocyte, and -T-cell aggregates were all significantly elevated in COVID-19 patients compared with healthy donors. Furthermore, platelets from COVID-19 patients aggregated faster and showed increased spreading on both fibrinogen and collagen. The increase in platelet activation and aggregation could partially be attributed to increased MAPK pathway activation and thromboxane generation. These findings demonstrate that SARS-CoV-2 infection is associated with platelet hyperreactivity, which may contribute to COVID-19 pathophysiology.

31 July 2019 in Blood
Verified
Journal Article
Open access
PDF file
EMElizabeth A. Middleton
Elizabeth A. Middleton
JRJesse W. Rowley
Jesse W. Rowley
RCRobert A. Campbell
Robert A. Campbell
CGColin K. Grissom
Colin K. Grissom
SBSamuel M. Brown
Samuel M. Brown
MRMatthew T. Rondina
Matthew T. Rondina
In a Plenary Paper, Middleton and colleagues describe important transcriptional and translational changes in murine and human platelets during sepsis, elucidating the emerging role of platelets in the complications of systemic inflammatory illness.

5 August 2021 in Blood
Verified
Journal Article
Open access
PDF file
LGLi Guo
Li Guo
SSSikui Shen
Sikui Shen
JRJesse W. Rowley
Jesse W. Rowley
NTNeal D. Tolley
Neal D. Tolley
WJWenwen Jia
Wenwen Jia
MRMatthew T. Rondina
Matthew T. Rondina
Circulating platelets interact with leukocytes to modulate host immune and thrombotic responses. In sepsis, platelet-leukocyte interactions are increased and have been associated with adverse clinical events, including increased platelet–T-cell interactions. Sepsis is associated with reduced CD8+ T-cell numbers and functional responses, but whether platelets regulate CD8+ T-cell responses during sepsis remains unknown. In our current study, we systemically evaluated platelet antigen internalization and presentation through major histocompatibility complex class I (MHC-I) and their effects on antigen-specific CD8+ T cells in sepsis in vivo and ex vivo. We discovered that both human and murine platelets internalize and proteolyze exogenous antigens, generating peptides that are loaded onto MHC-I. The expression of platelet MHC-I, but not platelet MHC-II, is significantly increased in human and murine platelets during sepsis and in human megakaryocytes stimulated with agonists generated systemically during sepsis (eg, interferon-γ and lipopolysaccharide). Upregulation of platelet MHC-I during sepsis increases antigen cross-presentation and interactions with CD8+ T cells in an antigen-specific manner. Using a platelet lineage–specific MHC-I–deficient mouse strain (B2Mf/f-Pf4Cre), we demonstrate that platelet MHC-I regulates antigen-specific CD8+ T-cell proliferation in vitro, as well as the number and functional responses of CD8+ T cells in vivo, during sepsis. Loss of platelet MHC-I reduces sepsis-associated mortality in mice in an antigen-specific setting. These data identify a new mechanism by which platelets, through MHC-I, process and cross-present antigens, engage antigen-specific CD8+ T cells, and regulate CD8+ T-cell numbers, functional responses, and outcomes during sepsis.

6 February 2020 in Blood
Verified
Journal Article
Closed access
PDF file
FDFrederik Denorme
Frederik Denorme
BMBhanu Kanth Manne
Bhanu Kanth Manne
IPIrina Portier
Irina Portier
AEAlicia S. Eustes
Alicia S. Eustes
YKYasuhiro Kosaka
Yasuhiro Kosaka
HCHeather Campbell
Heather Campbell
Platelets play critical roles in maintaining hemostasis. Dysregulated platelet functions contribute to both the development and progression of ischemic stroke. Utilizing mice with a platelet-specific deletion of cyclophilin D (CypD), a mediator of necrosis, we found that platelet necrosis regulates tissue damage and outcomes during ischemic stroke in vivo. Loss of CypD in platelets significantly enhanced cerebral blood flow, improved neurological and motor functions, and reduced ischemic stroke infarct volume after cerebral ischemia/reperfusion injury in mice. These effects were attributable, at least in part, to platelet-neutrophil interactions. Twenty-four hours after stroke, significantly fewer circulating platelet-neutrophil aggregates were found in CypD-deficient mice. Mice with CypD-deficient platelets also had less neutrophils recruited to their brain relative to wildtype counterparts, and cerebral platelet-neutrophil aggregates were virtually absent in mice with CypD-deficient platelets. Neutrophil depletion in wildtype mice conferred protection from ischemic stroke similarly to mice with CypD-deficient platelets. However, neutrophil depletion in mice with CypD-deficient platelets did not further reduce infarct size. These results suggest necrotic platelets interact with neutrophils to exacerbate brain injury following ischemic stroke. As inhibiting platelet necrosis does not compromise hemostasis, targeting platelet CypD may be a potential therapeutic strategy to limit brain damage following ischemic stroke.

8 September 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
KQKimberly A. Queisser
Kimberly A. Queisser
RMRebecca A. Mellema
Rebecca A. Mellema
EMElizabeth A. Middleton
Elizabeth A. Middleton
IPIrina Portier
Irina Portier
BMBhanu Kanth Manne
Bhanu Kanth Manne
APAaron C. Petrey
Aaron C. Petrey
Vascular injury has emerged as a complication contributing to morbidity in coronavirus disease 2019 (COVID-19). The glycosaminoglycan hyaluronan (HA) is a major component of the glycocalyx, a protective layer of glycoconjugates that lines the vascular lumen and regulates key endothelial cell functions. During critical illness, as in the case of sepsis, enzymes degrade the glycocalyx, releasing fragments with pathologic activities into circulation and thereby exacerbating disease. Here, we analyzed levels of circulating glycosaminoglycans in 46 patients with COVID-19 ranging from moderate to severe clinical severity and measured activities of corresponding degradative enzymes. This report provides evidence that the glycocalyx becomes significantly damaged in patients with COVID-19 and corresponds with severity of disease. Circulating HA fragments and hyaluronidase, 2 signatures of glycocalyx injury, strongly associate with sequential organ failure assessment scores and with increased inflammatory cytokine levels in patients with COVID-19. Pulmonary microvascular endothelial cells exposed to COVID-19 milieu show dysregulated HA biosynthesis and degradation, leading to production of pathological HA fragments that are released into circulation. Finally, we show that HA fragments present at high levels in COVID-19 patient plasma can directly induce endothelial barrier dysfunction in a ROCK- and CD44-dependent manner, indicating a role for HA in the vascular pathology of COVID-19.